| Code | CSB-RA012145MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody BC001, targeting KDR (Kinase Insert Domain Receptor), also known as VEGFR-2 (Vascular Endothelial Growth Factor Receptor 2). KDR is a type III receptor tyrosine kinase that plays a critical role in vasculogenesis and angiogenesis by mediating endothelial cell proliferation, migration, and survival in response to VEGF binding. This receptor is predominantly expressed on vascular endothelial cells and represents a key regulator of both physiological and pathological blood vessel formation. Aberrant KDR signaling is implicated in various disease states, including tumor angiogenesis, diabetic retinopathy, age-related macular degeneration, and cardiovascular disorders.
BC001, also known as ramucirumab injection, is a biosimilar drug of an anti-VEGFR2 humanized monoclonal antibody. It binds to and blocks VEGFR2 with high affinity, inhibiting tumor angiogenesis, cutting off the tumor's nutrient supply, thereby suppressing tumor growth. It has been approved for use mainly in the treatment of advanced gastric cancer or adenocarcinoma of the gastroesophageal junction (usually in combination with paclitaxel, for patients who have failed first-line chemotherapy). This biosimilar antibody provides researchers with a reliable reagent for investigating KDR-mediated signaling pathways, studying anti-angiogenic mechanisms, evaluating therapeutic targets in oncology, and exploring vascular biology in various disease models. It serves as a valuable tool for understanding VEGF/VEGFR-2 axis regulation and its implications in tumor progression and vascular-related pathologies.
There are currently no reviews for this product.